Annual revenue rose 92.2% from KRW 78.3 billion in 2022 to KRW 150.6 billion in 2023, the largest year in the 2022–2025 window. Revenue then fell 0.3% to KRW 150.1 billion in 2024 and 21.4% to KRW 118 billion in 2025, a decline for two consecutive years.
Operating losses were KRW 119.3 billion in 2022, KRW 88.9 billion in 2023, KRW 86.8 billion in 2024 and KRW 95.6 billion in 2025, so the company has been loss-making for four consecutive years, with the loss widening again in 2025.
The operating margin improved from -152.3% in 2022 to -59.0% in 2023 and -57.8% in 2024, then deteriorated to -81.0% in 2025. The net loss attributable to controlling shareholders narrowed from KRW 98.7 billion in 2022 to KRW 55.6 billion in 2023, then widened to KRW 58.1 billion in 2024 and KRW 70.2 billion in 2025.
The consolidated net loss, which includes non-controlling interests, was KRW 140.6 billion in 2025, a much larger figure than the controlling-shareholder figure.
The debt ratio rose from 30.1% in 2022 to 56.4% in 2025, with total liabilities of KRW 258.7 billion at the end of 2025 against total equity of KRW 458.6 billion, of which KRW 158.3 billion belonged to controlling shareholders.
Operating cash outflow narrowed from KRW -113.5 billion in 2022 to KRW -32.7 billion in 2025, but it has been negative in each of the four years. Data Daily reported that receivables reached KRW 61.22 billion in 2025, up 148.7% year on year even as revenue declined.
On a quarterly basis, revenue fell from KRW 35.6 billion in the third quarter of 2025 to KRW 31.5 billion in the fourth quarter, recovered to KRW 36.3 billion in the first quarter of 2026, then declined to KRW 35.5 billion in the second quarter and KRW 34.6 billion in the third quarter of 2026.
The operating loss narrowed to KRW 13.3 billion in the third quarter of 2026 from KRW 22.4 billion in the second quarter, while the net loss attributable to controlling shareholders widened from KRW 25.5 billion to KRW 38.5 billion over the same period.
Medico Pharma reported that the subsidiary Aprogen Biologics booked only about KRW 0.2 billion of bio manufacturing service revenue in the first quarter of 2026.